Kyverna Therapeutics KYTX Ratios (2023-2026)

NASDAQ KYTX
$8.26 -0.09 (-1.08%)
As of: Sep 4, 2026 · 3:58 PM EDT
Reported Financials

Kyverna Therapeutics Quarterly Ratios

Periods 14 quarters
Latest Jun 2026

Kyverna Therapeutics ratios data for the quarter ended Jun 2026. These financial ratios cover 14 quarters of results from Mar 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Ratios Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Efficiency
Assets AverageAssets Avg. 232.59M376.55M351.16M321.92M282.65M243.58M206.83M240.49M275.43M238.42M
Invested CapitalInvested Cap. 266.59M257.02M220.39M190.43M
Leverage & Solvency
Interest Coverage RatioInterest Cover -260.11-289.17-325.64-454.83-667.23-857.31-0.00M-0.00M-0.00M-0.00M-0.01M-88.47-62.02-58.69
Debt Ratio 0.080.100.11
Times Interest Earned -260.11-289.17-325.64-454.83-667.23-857.31-0.00M-0.00M-0.00M-0.00M-0.01M-88.47-62.02-58.69
Valuation
Price to EarningsP/E -22.13-11.24-6.13-4.31-1.87-3.16-7.15-11.00-13.16-14.32
Price to BookP/B 1.630.970.700.610.370.721.731.792.673.31
Enterprise Value 220.26M-22.64M-110.50M-124.36M-159.25M-78.92M91.60M136.75M285.90M349.16M
EV to EBIT -7.500.682.853.033.361.78-2.37-3.48-6.91-8.83
EV to EBITDA -7.500.682.853.033.361.78-2.37-3.48-6.91-8.83
Market Capitalization 590.05M323.60M211.09M161.62M83.41M132.76M262.76M416.04M522.40M548.59M
Price to FCFP/FCF -22.64-12.84-7.65-4.29-1.84-4.15-5.94-12.53-12.56-14.15
EV to FCF -8.450.904.003.303.512.47-2.07-4.12-6.87-9.01
EV to CFO -8.630.944.023.353.552.47-2.12-4.08-6.87-8.66
Return Ratios
Return on Capital Employed [ROCE]ROCE -38.12%-28.45%-38.40%-49.49%-64.43%-84.22%-99.21%-83.25%-66.65%-73.71%
Return on Assets [ROA]ROA -32.61%-24.31%-31.48%-39.57%-51.42%-65.11%-77.79%-67.04%-56.76%-63.99%